BCR and non-small cell lung carcinoma: Important druggable targets, biomarkers and signaling components related to either NSCLC or BCR signaling pathways were identified and quantified in low-scale samples, demonstrating the promising applicability of the chip-DIA workflow for both cell biology and clinical proteomics research.